{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:24:32Z","timestamp":1790663072758,"version":"4.1.0"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The pharmacotherapy of inflammatory bowel diseases (Crohn\u2019s disease and ulcerative colitis) has experienced significant progress with the advent of monoclonal antibodies (mABs). As therapeutic proteins, mABs display peculiar pharmacokinetic characteristics that differentiate them from chemical drugs, such as aminosalicylates, antimetabolites (i.e., azathioprine, 6-mercaptopurine, and methotrexate), and immunosuppressants (corticosteroids and cyclosporine). However, clinical trials have demonstrated that biologic agents may suffer from a pharmacokinetic variability that could influence the desired clinical outcome, beyond primary resistance phenomena. Therefore, therapeutic drug monitoring (TDM) protocols have been elaborated and applied to adaptation drug doses according to the desired plasma concentrations of mABs. This activity is aimed at maximizing the beneficial effects of mABs while sparing patients from toxicities. However, some aspects of TDM are still under discussion, including time-changing therapeutic ranges, proactive and reactive approaches, the performance and availability of instrumental platforms, the widely varying individual characteristics of patients, the severity of the disease, and the coadministration of immunomodulatory drugs. Facing these issues, personalized medicine in IBD may benefit from a combined approach, made by TDM protocols and pharmacogenetic analyses in a timeline that necessarily considers the frailty of patients, the chronic administration of drugs, and the possible worsening of the disease. Therefore, the present review presents and discusses the activities of TDM protocols using mABs in light of the most recent results, with special attention on the integration of other actions aimed at exploiting the most effective and safe therapeutic effects of drugs prescribed in IBD patients.<\/jats:p>","DOI":"10.3389\/fphar.2020.610806","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T23:50:04Z","timestamp":1612828204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond"],"prefix":"10.3389","volume":"11","author":[{"given":"Antonello","family":"Di Paolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Luci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/ijms20102529","article-title":"A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease","volume":"20","author":"Aardoom","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with crohn's disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clinthera.2019.11.010","article-title":"Population pharmacokinetics and exposure-response modeling of golimumab in adults with moderately to severely active ulcerative colitis","volume":"42","author":"Adedokun","year":"2020","journal-title":"Clin. Therapeut."},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J. Crohns. Colitis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1124\/dmd.114.058917","article-title":"Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry","volume":"42","author":"An","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/apt.15762","article-title":"Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease","volume":"51","author":"Bangma","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/tpj.2014.19","article-title":"Associations between functional polymorphisms in the NF\u03baB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease","volume":"14","author":"Bank","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/apt.15187","article-title":"Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease","volume":"49","author":"Bank","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1080\/21645515.2019.1591139","article-title":"A product review of vedolizumab in inflammatory bowel disease. Hum. Vaccin. Immunother","volume":"15","author":"Battat","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ibd\/izz143","article-title":"Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease","volume":"26","author":"Bauman","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/138920006774832604","article-title":"Early development of therapeutic biologics--pharmacokinetics","volume":"7","author":"Baumann","year":"2006","journal-title":"Curr. Drug Metabol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/apt.13736","article-title":"Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases","volume":"44","author":"Bek","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/00365521.2019.1619828","article-title":"Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study","volume":"54","author":"Berends","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/ajg.2016.306","article-title":"A genetic variation in the neonatal fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease","volume":"111","author":"Billiet","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3109\/00365521.2016.1157894","article-title":"Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease","volume":"51","author":"Bodini","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/ibd\/izz199","article-title":"Identification of target golimumab levels in maintenance therapy of crohn's disease and ulcerative colitis associated with mucosal healing","volume":"26","author":"Boland","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ibd\/izx065","article-title":"Combination immunosuppression in IBD","volume":"24","author":"Bots","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/00365521.2019.1582693","article-title":"Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy","volume":"54","author":"Bots","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"B19","volume-title":"Principles of N-linked glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional considerations","author":"Boune","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","article-title":"Predictors of dose escalation of adalimumab in a prospective cohort of Crohn\u2019s disease patients","volume":"35","author":"Bultman","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/ibd\/izy083","article-title":"Genetic markers predict primary nonresponse and durable response to anti-tumor necrosis factor therapy in ulcerative colitis","volume":"24","author":"Burke","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10928-013-9332-2","article-title":"Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"40","author":"Cao","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11894-018-0623-z","article-title":"Therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"20","author":"Carman","year":"2018","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ajg.2016.569","article-title":"Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study","volume":"112","author":"Casanova","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.aca.2018.02.040","article-title":"Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS\/MS","volume":"1019","author":"Chiu","year":"2018","journal-title":"Anal. Chim. Acta"},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","article-title":"Development of infliximab target concentrations during induction in pediatric crohn disease patients","volume":"69","author":"Clarkston","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"B31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cgh.2013.10.025","article-title":"Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2013.08.035","article-title":"Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn","volume":"1534","author":"Cooper","year":"2013","journal-title":"Brain Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in treatment of Crohn\u2019s disease: design, development, and potential place in therapy","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40262-018-0639-4","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory bowel disease","volume":"57","author":"Derijks","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3389\/fonc.2019.01417","article-title":"Precision medicine in lymphoma by innovative instrumental platforms","volume":"9","author":"Di Paolo","year":"2019","journal-title":"Front. Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ibd\/izz144","article-title":"A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis","volume":"26","author":"Dreesen","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of Vedolizumab Trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ibd.21174","article-title":"Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease","volume":"16","author":"Dubinsky","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11894-016-0522-0","article-title":"Next-generation therapeutics for inflammatory bowel disease","volume":"18","author":"Dulai","year":"2016","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.4155\/bio-2018-0091","article-title":"Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics","volume":"10","author":"Egging","year":"2018","journal-title":"Bioanalysis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/FTD.0000000000000633","article-title":"Simultaneous quantification of free adalimumab and infliximab in human plasma using a target-based sample purification and liquid chromatography-tandem mass spectrometry","volume":"41","author":"El Amrani","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"B44","volume-title":"Vedolizumab","author":"EMA","year":"2018"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Fox","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/flgastro-2016-100685","article-title":"Use of anti-TNF drug levels to optimise patient management","volume":"7","author":"Gastonguay","year":"2016","journal-title":"Frontline Gastroenterol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s002770050396","article-title":"The IgG Fc receptor family","volume":"76","author":"Gessner","year":"1998","journal-title":"Ann. Hematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1185\/03007995.2010.481203","article-title":"Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations","volume":"26","author":"Gibney","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"B53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/apt.15643","article-title":"Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease","volume":"51","author":"Gibson","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/JIR.S121233","article-title":"Fc gamma receptors: glycobiology and therapeutic prospects","volume":"9","author":"Hayes","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ecco-jcc\/jjv219","article-title":"Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease","volume":"10","author":"Heap","year":"2016","journal-title":"J. Crohns. Colitis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.3093","article-title":"HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants","volume":"46","author":"Heap","year":"2014","journal-title":"Nat. Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","article-title":"The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients?","volume":"12","author":"Hindryckx","year":"2018","journal-title":"J. Crohns. Colitis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","article-title":"Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn","volume":"89","author":"Israel","year":"1996","journal-title":"Immunology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/MOP.0000000000000529","article-title":"The use of biosimilars in paediatric inflammatory bowel disease","volume":"29","author":"Jongsma","year":"2017","journal-title":"Curr. Opin. Pediatr."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","article-title":"Infliximab in young paediatric IBD patients: it is all about the dosing","volume":"179","author":"Jongsma","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/FTD.0000000000000514","article-title":"Simultaneous quantification of adalimumab and infliximab in human plasma by liquid chromatography-tandem mass spectrometry","volume":"40","author":"Jourdil","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/jgh.14652","article-title":"ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases","volume":"34","author":"Jung","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","article-title":"NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study","volume":"53","author":"Kakuta","year":"2018","journal-title":"J. Gastroenterol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2018.09.004","article-title":"Personalized treatment in inflammatory bowel disease: for another time","volume":"155","author":"Kaneider","year":"2018","journal-title":"Gastroenterology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1515\/cclm.1992.30.4.197","article-title":"Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis","volume":"30","author":"Kapel","year":"1992","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clim.2018.03.004","article-title":"Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies","volume":"206","author":"Katsanos","year":"2019","journal-title":"Clin. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12407","article-title":"Review article: a clinician\u2019s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease","volume":"38","author":"Khanna","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","article-title":"Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model","volume":"122","author":"Kim","year":"2007","journal-title":"Clin. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical pharmacokinetics and use of infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"B75","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00228-012-1389-0","article-title":"Influence of polymorphisms and TNF and IL1\u03b2 serum concentration on the infliximab response in Crohn's disease and ulcerative colitis","volume":"69","author":"Lacruz-Guzm\u00e1n","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40265-017-0765-6","article-title":"Ustekinumab: a review in moderate to severe crohn\u2019s disease","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"B77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ibd\/izy203","article-title":"Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD","volume":"25","author":"Lega","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.biologicals.2011.06.002","article-title":"Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials","volume":"39","author":"Liu","year":"2011","journal-title":"Biologicals"},{"key":"B79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1208\/s12248-016-9981-3","article-title":"Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade\u00ae","volume":"19","author":"Lora","year":"2017","journal-title":"AAPS J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/genes10040277","article-title":"Azathioprine biotransformation in young patients with inflammatory bowel disease: contribution of glutathione-S transferase M1 and A1 variants","volume":"10","author":"Lucaf\u00f2","year":"2019","journal-title":"Genes"},{"key":"B82","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11936-010-0094-5","article-title":"Subcutaneous administration of biotherapeutics: current experience in animal models","volume":"12","author":"McDonald","year":"2010","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"Morell","year":"1970","journal-title":"J. Clin. Invest."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00216-018-0848-6","article-title":"Development of an LC-MS\/MS peptide mapping protocol for the NISTmAb","volume":"410","author":"Mouchahoir","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.14318","article-title":"Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn\u2019s disease: a subanalysis of the DIAMOND trial","volume":"46","author":"Nakase","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1007\/s10620-018-5144-y","article-title":"Comparison of point-of-care and classical immunoassays for the monitoring infliximab and antibodies against infliximab in IBD","volume":"63","author":"Nasser","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bcp.13845","article-title":"New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases","volume":"85","author":"Nemoz","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/apt.16135","article-title":"Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays","volume":"53","author":"Nice","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2019.09167","article-title":"Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn\u2019s disease. Int. Res. [Epub ahead of print]","author":"Okamoto","year":"2020"},{"key":"B92","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MEG.0000000000001332","article-title":"Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab","volume":"31","author":"Orfanoudaki","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MOG.0000000000000536","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?","volume":"35","author":"Papamichael","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease","volume":"13","author":"Papamichael","year":"","journal-title":"J. Crohns. Colitis"},{"key":"B98","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","article-title":"Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease","volume":"12","author":"Papamichael","year":"2018","journal-title":"J. Crohns. Colitis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases","volume":"15","author":"Papamichael","year":"","journal-title":"Expet Rev. Clin. Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"105120","DOI":"10.1016\/j.phrs.2020.105120","article-title":"Biological therapy in pediatric age","volume":"161","author":"Penagini","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12916-019-1323-8","article-title":"Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview","volume":"17","author":"Pouillon","year":"2019","journal-title":"BMC Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00228-015-1862-7","article-title":"Review article: the pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment","volume":"71","author":"Quetglas","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","article-title":"Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis","volume":"12","author":"Ricciuto","year":"2018","journal-title":"J. Crohns. Colitis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"key":"B105","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7150\/ijms.22812","article-title":"A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF","volume":"15","author":"Romero-Cara","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or crohn\u2019s disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J. Crohns. Colitis"},{"key":"B108","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.dld.2008.03.016","article-title":"The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice","volume":"40","author":"Saibeni","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.3390\/ijms21093364","article-title":"Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease","volume":"21","author":"Salvador-Mart\u00edn","year":"2020","journal-title":"Ijms"},{"key":"B110","doi-asserted-by":"publisher","first-page":"105369","DOI":"10.1016\/j.ejps.2020.105369","article-title":"Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease","volume":"150","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/FTD.0000000000000669","article-title":"Predictors of Infliximab Trough concentrations in inflammatory bowel disease patients using a repeated-measures design","volume":"42","author":"Santacana","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"B115","article-title":"Bayes\u2010based dosing of infliximab in inflammatory bowel diseases: short\u2010term efficacy. Br. J. Clin. Pharmacol. [Epub ahead of print].","author":"Santacana Juncosa","year":"2020"},{"key":"B116","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1515\/cclm-2015-0987","article-title":"Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits","volume":"54","author":"Schmitz","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/00365521.2018.1452974","article-title":"A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients","volume":"53","author":"Schulze","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/ecco-jcc\/jjaa029","article-title":"Is therapeutic drug monitoring for anti-tumour necrosis factor Agents in adults with inflammatory bowel disease ready for standard of care? A systematic review and meta-analysis","volume":"14","author":"Shah","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"B121","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/ecco-jcc\/jjz009","article-title":"Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease","volume":"13","author":"Sluiter","year":"2019","journal-title":"J. Crohns. Colitis"},{"key":"B124","doi-asserted-by":"publisher","first-page":"S063","DOI":"10.1093\/ecco-jcc\/jjy222.090","article-title":"DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial","volume":"13","author":"Strik","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2018.06.077","article-title":"Gene expression signature for prediction of golimumab response in a phase 2a open-label trial of patients with ulcerative colitis","volume":"155","author":"Telesco","year":"2018","journal-title":"Gastroenterology"},{"key":"B127","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"B128","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of tnf inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"B129","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and Adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/FTD.0000000000000310","article-title":"Comparison of three assays to quantify infliximab, adalimumab, and etanercept serum concentrations","volume":"38","author":"van Bezooijen","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"B131","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/MPG.0000000000002265","article-title":"Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease","volume":"68","author":"van Hoeve","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher Infliximab Trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"","journal-title":"J. Crohns. Colitis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/ecco-jcc\/jjz050","article-title":"Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in crohn\u2019s disease: a prospective multicentre study","volume":"13","author":"Vande Casteele","year":"2019","journal-title":"J. Crohns. Colitis"},{"key":"B134","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/apt.14421","article-title":"Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease","volume":"47","author":"Vande Casteele","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough Concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-017-0535-3","article-title":"Accounting for pharmacokinetic variability of certolizumab pegol in patients with crohn's disease","volume":"56","author":"Vande Casteele","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B137","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14740338.2018.1413090","article-title":"Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease","volume":"17","author":"Vermeire","year":"","journal-title":"Expet Opin. Drug Saf."},{"key":"B138","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1093\/hmg\/ddz189","article-title":"Rare and common variant discovery in complex disease: the IBD case study","volume":"28","author":"Venkataraman","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cgh.2019.09.041","article-title":"How, when, and for whom should we perform therapeutic drug monitoring?","volume":"18","author":"Vermeire","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3748\/wjg.v25.i21.2539","article-title":"Predicting (side) effects for patients with inflammatory bowel disease: the promise of pharmacogenetics","volume":"25","author":"Voskuil","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.491","article-title":"Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease","volume":"55","author":"Wade","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2036.2009.04073.x","article-title":"Efficacy of methotrexate in Crohn\u2019s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine\/mercaptopurine","volume":"30","author":"Wahed","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1172\/JCI107023","article-title":"The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia","volume":"51","author":"Waldmann","year":"1972","journal-title":"J. Clin. Invest."},{"key":"B144","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jama.2019.0709","article-title":"Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease","volume":"321","author":"Walker","year":"2019","journal-title":"J. Am. Med. Assoc."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ecco-jcc\/jjz017","article-title":"Novel genetic risk variants can predict anti-TNF agent response in patients with inflammatory bowel disease","volume":"13","author":"Wang","year":"2019","journal-title":"J. Crohns. Colitis"},{"key":"B146","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.aca.2019.03.033","article-title":"A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn\u2019s disease","volume":"1067","author":"Willeman","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within six months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1208\/s12248-017-0082-8","article-title":"Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies","volume":"19","author":"Wojciechowski","year":"2017","journal-title":"AAPS J."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/glycob\/10.12.1347","article-title":"In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure","volume":"10","author":"Wright","year":"2000","journal-title":"Glycobiology"},{"key":"B151","doi-asserted-by":"publisher","first-page":"14644","DOI":"10.1111\/imj.14644","article-title":"Therapeutic drug monitoring in Inflammatory Bowel Disease reduces unnecessary use of infliximab with substantial associated cost\u2010savings","author":"Wu","year":"2019","journal-title":"Intern. Med. J."},{"key":"B152","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/jcph.1582","article-title":"Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis","volume":"60","author":"Xu","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/jcph.1353","article-title":"Population pharmacokinetics and exposure\u2010response modeling analyses of golimumab in children with moderately to severely active ulcerative colitis","volume":"59","author":"Xu","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0091270009340782","article-title":"Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects","volume":"50","author":"Xu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MOG.0000000000000444","article-title":"Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways","volume":"34","author":"Yamamoto-Furusho","year":"2018","journal-title":"Curr. Opin. Gastroenterol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cgh.2014.12.026","article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","volume":"13","author":"Yarur","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/jcph.4","article-title":"The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model","volume":"53","author":"Zhao","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bcp.2019.04.020","article-title":"Comprehensive study of thiopurine methyltransferase genotype, phenotype, and genotype-phenotype discrepancies in Sweden","volume":"164","author":"Zimdahl Kahlin","year":"2019","journal-title":"Biochem. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.610806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T23:50:06Z","timestamp":1612828206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.610806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":160,"alternative-id":["10.3389\/fphar.2020.610806"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.610806","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"article-number":"610806"}}